Item 8.01. Other Events.

On June 10, 2009, BioMarin Pharmaceutical Inc. ("BioMarin") completed the purchase of all the outstanding shares of capital stock of BioMarin Pediatrics II (formerly known as Ascent Pediatrics, Inc. and Medicis Pediatrics, Inc.) ("Pediatrics") a wholly-owned subsidiary of Medicis Pharmaceutical Corporation ("Medicis") (the "Closing"). Pediatrics' sole substantial asset is the intellectual property related to the Orapred franchise. As previously disclosed, BioMarin expected to purchase the outstanding shares of Pediatrics in August 2009, but BioMarin and Medicis agreed to close the transaction early in order to settle an outstanding claim related to certain transition services. At the closing, BioMarin paid Medicis $70.6 million in cash as consideration for the stock. The purchase was completed substantially in accordance with the terms of the previously disclosed Securities Purchase Agreement dated May 18, 2004 and amended on January 12, 2005, by and among BioMarin, Medicis and Pediatrics.

The financial impact of this transaction will be reflected in BioMarin's Form 10-Q for its second quarter ending June 30, 2009. Following the Closing, BioMarin intends to transfer all of the North American intellectual property relating to the Orapred product to Sciele Pharma, Inc., a U.S.-based group company of Shionogi & Co., the third party who holds a license from BioMarin to sell and commercialize the Orapred product line in North America. This transfer of the intellectual property will be made in accordance with the terms of the previously disclosed License Agreement dated March 15, 2006 between Biomarin and Sciele Pharma, Inc. (formerly Alliant Pharmaceuticals, Inc.).

---